M0001 Advancing Cancer Care (HCPCS) Reimbursement | OpenPayer

Summary & Overview

HCPCS M0001: Advancing Cancer Care MIPS Value Pathways

HCPCS Level II code M0001 denotes services tied to advancing cancer care through MIPS value pathways, emphasizing structured quality reporting and care coordination in oncology. As national efforts shift toward value-based models, this code captures activities that align clinical practice with performance measurement and pathway-based care delivery for patients with cancer. The code is relevant to oncology clinicians, cancer centers, payers, and policy stakeholders focused on measurement-driven improvements in cancer outcomes.

Key payers in the coverage context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what M0001 represents, the typical settings where related services occur, and which major payers are included in the analysis. The publication outlines benchmarks, policy and billing considerations, and clinical context for implementing MIPS-aligned oncology value pathways where available.

This summary provides a national perspective on the code’s role in value-based oncology care, what to expect in payer engagement, and the types of measures and reporting activities associated with MIPS value pathways. Data not available in the input will be noted where relevant.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM0001HCPCS Level IIoncologyMIPSvalue-based carequality reportingcare coordinationoutpatient oncology

Billing Code Overview

HCPCS Level II code M0001 represents Advancing cancer care mips value pathways. The service focuses on pathways and quality reporting frameworks intended to support value-based cancer care through the Merit-based Incentive Payment System (MIPS) pathway alignment and quality measure reporting.

Service Type: Quality reporting and care pathway coordination focused on oncology value pathways
Typical Site of Service: Outpatient oncology settings, cancer centers, and clinician offices delivering cancer care coordination and quality reporting activities

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with newly diagnosed metastatic colorectal cancer is enrolled in a quality improvement program focusing on advancing cancer care through the MIPS Value Pathways (MVP) for oncology. The patient presents to a multidisciplinary cancer center for coordinated care planning that includes oncology medical management, radiation oncology consultation, genetic counseling, and palliative care assessment. The clinical workflow begins with an initial oncologist visit to review staging and systemic therapy options, followed by documentation of baseline performance status, goals-of-care discussion, and referral orders for next-step services (chemotherapy infusion scheduling, radiation consult if indicated, germline and tumor genomic testing, and supportive care services). The care team captures quality and cost measures required by the MIPS MVP, coordinates transitions between outpatient and infusion center, documents shared decision-making, documents any adverse events during treatment, and reports MVP measures during the performance period.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work, time, technical skill, or intensity of services provided is substantially greater than typically required for the procedure.
`23`

HCPCS M0002: Optimal Care for Kidney Health MIPS Value Pathways

HCPCS-M0003-EPISODIC-NEUROLOGICAL-CARE-VALUE-PATHWAY

HCPCS M0003: Optimal Care for Episodic Neurological Conditions

HCPCS-M0005-PRIMARY-CARE-MIPS-VALUE-PATHWAY

HCPCS M0005: Value in Primary Care MIPS Value Pathway

HCPCS-M0004-QUALITY-CARE-NEUROLOGICAL-CONDITIONS-MIPS

HCPCS M0004: Quality Care for Patients with Neurological Conditions

Taxonomy Code	Specialty	Notes
207RH0000X	Hematology & Medical Oncology	Primary specialty coordinating systemic cancer therapy and MIPS reporting.
207K00000X	Radiation Oncology	Provides radiation evaluation and treatment when indicated within the MVP pathway.
208000000X	General Surgery	Performs oncologic surgical procedures when resection is part of the care plan.
2084P0800X	Palliative Medicine	Provides symptom management and goals-of-care discussions integrated into MVP measures.
363L00000X	Clinical Geneticist	Performs germline testing coordination and interpretation when precision oncology measures apply.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Metastatic involvement commonly encountered in advanced colorectal and other cancers enrolled in MVP pathways.
`C18.9`	Malignant neoplasm of colon, unspecified	Primary diagnosis commonly managed within an advancing cancer care MIPS pathway.
`C50.912`	Malignant neoplasm of unspecified site of right female breast	Breast cancer presentations are included in MVP oncology measures and care coordination workflows.
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Lung cancer is a frequent MVP oncology focus guiding systemic and local therapy decisions.
`C61`	Malignant neoplasm of prostate	Prostate cancer care coordination and quality measures may be included in oncology MVP reporting.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug	Commonly performed during systemic therapy visits coordinated within the MVP pathway.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Used for oncology follow-up visits where treatment decisions and MIPS documentation occur.
`77427`	Radiation treatment management, 5 treatments	Used for radiation oncology management visits when radiation therapy is part of the care plan.
`88342`	Surgical pathology, gross and microscopic examination	Used for pathologic evaluation of tumor specimens supporting diagnosis and treatment planning.
`81275`	KRAS mutation analysis by PCR or sequencing (example molecular pathology)	Represents tumor genomic testing that informs targeted therapy decisions reported within MVP measures.
`86308`	Tumor marker immunoassay (e.g., carcinoembryonic antigen)	Used for baseline or surveillance biomarker testing as part of care coordination in the MVP.

OpenPayer